November 17, 2022
|
Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
|
|
November 16, 2022
|
Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors
|
|
November 4, 2022
|
Ayala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
|
|
October 19, 2022
|
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
|
|
September 29, 2022
|
Ayala Pharmaceuticals to Host Key Opinion Leader Webinar on Desmoid Tumors
|
|
September 27, 2022
|
Ayala Pharmaceuticals Announces Fast Track Designation Granted by US FDA for AL102 in Progressing Desmoid Tumors
|
|
September 12, 2022
|
Ayala Pharmaceuticals Presents Positive Interim Data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors at ESMO Congress 2022
|
|
August 24, 2022
|
Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 Congress
|
|
August 15, 2022
|
Ayala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
|
|
July 5, 2022
|
Ayala Pharmaceuticals Announces Interim Data from Part A of the Phase 2/3 RINGSIDE Trial of AL102 in Desmoid Tumors
|
|